Shivom is a global blockchain-genomics ecosystem powering the next era of precision medicine. Shivom is building a genomic and health data hub by combining blockchain, genomic DNA sequencing, artificial intelligence and cryptography to power secure and personalized medicine.

Shivom works on principles of collaboration and integrity, allowing users to own, manage and monetize their genomics and health data. The Shivom team aims to reach even underserved and low-income countries where such services have not been previously available. This solution will create shared value for individuals, not-for-profit organizations, governments, and for-profit entities alike.

Project Shivom Telegram: https://t.me/projshivom

Team:

• Dr. Axel Schumacher: Co-Founder & CEO.
• Gourish Singla: Co-Founder & CSO.
• Sally Eaves: Co-Founder & CMO.
• Henry Ines: Chief innovation officer.
• Akash Gaurav: Co-Founder & CTO.
• Dr. Natalie Pankova: Chief scientific officer.
• Dr. Rashad Ibrahim: Head of Middle East.
• Agam Kansal: VP marketing.
• Charles Leslie: Investment lead.
• Ajit Singh Kular: Head of digital marketing.
• Azam Shaghaghi: Head of public relations.
• Kayleen Schreiber: Design lead.
• Pierre Maarek: Investment lead.

Shivom will be holding its ICO in two phases, the pre-sale starts on the 16th of April, 2018 and is expected to end on the 22nd of April, 2018. The main sale is set to start on the 3rd of May, 2018 and is planned to end on the 10th of May, 2018 or when the funding cap is reached. The ICO token supply represents 33% of the total token supply, so there will be a total of 990,000,000 tokens available, for 0.00014 ETH each during the offering. The ICO funding cap is 35,000,000 USD. Any unsold/remaining tokens will be burned.

Token Reserve Split (67%):

• 20% Pool;
• 20% Reserve;
• 14% Founders;
• 10% Advisors;
• 3% Community;

Shivom ICO will feature a bonus program and a bounty campaign, and the token will not be mineable.